HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker?

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1157-1162

  Bussu, F ^a   Sali, M ^a   Gallus, R ^a   Vellone, V G ^a   Zannoni, G F ^a   Autorino, R ^a   Dinapoli, N ^a   Santangelo, R ^a   Martucci, R ^a   Graziani, C ^a   Micciche F ^a   Almadori, G ^a   Galli, J ^a   Delogu, G ^a   Sanguinetti, M ^a   Rindi, G ^a   Valentini, V ^a   Paludetti, G ^a  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

diagnostic assay; head and neck carcinogenesis; HPV infection; molecular characterisation; p16 immunohistochemistry

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PROTEIN P16; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; GENETIC RISK; GENOTYPE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; HYPOPHARYNX; IMMUNOHISTOCHEMISTRY; LARYNX; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROGNOSIS;

EID: 84875473930     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.55     Document Type: Article

References (48)

1. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN (2011) Exome sequencing of head and neck squamous cellcarcinoma reveals inactivating mutations in NOTCH1. Science 333 (6046) :1154-1157.
2. Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M (2005) Molecular markers in laryngeal squamous cell carcinoma: towards anintegrated clinicobiological approach. Eur J Cancer 41 (5) : 683-693.
3. Almadori G, Bussu F, Paludetti G (2008) Should there be more molecularstaging of head and neck cancer to improve the choice of treatments andthereby improve survival? Curr Opin Otolaryngol Head Neck Surg 16 2 117-126.
4. Almadori G, Cadoni G, Cattani P, Galli J, Bussu F, Ferrandina G, Scambia G, Fadda G, Maurizi M (2001) Human papillomavirus infection andepidermal growth factor receptor expression in primary laryngealsquamous cell carcinoma. Clin Cancer Res 7 (12) : 3988-3993.
5. Almadori G, Galli J, Cadoni G, Bussu F, Maurizi M (2002) Humanpapillomavirus infection and cyclin D1 gene amplification in laryngealsquamous cell carcinoma: biologic function and clinical significance. HeadNeck 24 (6) : 597-604.
6. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, SilvermanCC, Redmond KP, Gillison ML (2010) Human papillomavirus andsurvival of patients with oropharyngeal cancer. N Engl J Med 363 (1) :24-35.
7. Bosch FX, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A, Hergenhahn M, Weidauer H (2004) Head and neck tumor sites differ inprevalence and spectrum of p53 alterations but these have limitedprognostic value. Int J Cancer 111 (4) : 530-538.
8. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, brahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) A review of humancarcinogens-Part B: biological agents. Lancet Oncol 10 (4) : 321-322.
9. Braakhuis BJ, Brakenhoff RH, Meijer CJ, Snijders PJ, Leemans CR (2009) Human papilloma virus in head and neck cancer: the need for astandardised assay to assess the full clinical importance. Eur J Cancer45 (17) : 2935-2939.
10. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH (2004) Genetic patterns in head and neckcancers that contain or lack transcriptionally active humanpapillomavirus. J Natl Cancer Inst 96 (13) : 998-1006.
11. Bray F, Sankila R, Ferlay J, Parkin DM (2002) Estimates of cancer incidenceand mortality in Europe in 1995. Eur J Cancer 38 (1) : 99-166.
12. Bussu F, Ranelletti FO, Gessi M, Graziani C, Lanza P, Lauriola L, Paludetti G, Almadori G (2012) Immunohistochemical expression patterns of theHER4 receptors in normal mucosa and in laryngeal squamous cellcarcinomas: antioncogenic significance of the HER4 protein in laryngealsquamous cell carcinoma. Laryngoscope 122: 1724-1733.
13. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, JiangB, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, WentzensenN, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidencein the United States. J Clin Oncol 29 (32) : 4294-4301.
14. De Vita V, Lawrence T, Rosenberg S, DePinho R, Weinberg R (2008) DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology.8th edn (Lippincott Williams & Wilkins.
15. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma geneproduct. Science 243 (4893) : 934-937.
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCCCancer Staging Manual. Springer New York, NY.
17. El-Naggar AK, Westra WH (2011) P16 expression as a surrogate marker forHPV-related oropharyngeal carcinoma: a guide for interpretativerelevance and consistency. Head Neck 34: 459-461.
18. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancerincidence and mortality in Europe in 2008. Eur J Cancer 46 (4) : 765-781.
19. Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, Sartor G, Politi D, Trovo MG, Barzan L (2003) Radiotherapy for patients with early-stageglottic carcinoma: univariate and multivariate analyses in a group ofconsecutive, unselected patients. Cancer 98 (4) : 765-772.
20. Gillison ML (2009) HPV and prognosis for patients with oropharynx cancer.Eur J Cancer 45 (Suppl 1) : 383-385.
21. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, ZahurakML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and asubset of head and neck cancers. J Natl Cancer Inst 92 (9) : 709-720.
22. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T, Munck-Wikland E (2006) Human papillomavirus as a risk factor for the increase in incidenceof tonsillar cancer. Int J Cancer 119 (11) : 2620-2623.
23. Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME, Kimple RJ (2011) Association of p16 (INK4a) overexpression with improved outcomes inyoung patients with squamous cell cancers of the oral tongue. Head Neck33 (11) : 1622-1627.
24. Heath S, Willis V, Allan K, Purdie K, Harwood C, Shields P, Simcock R, Williams T, Gilbert DC (2012) Clinically significant human papillomavirus in squamous cell carcinoma of the head and neck in UK practice.Clin Oncol (R Coll Radiol ) 24 (1) : e18-e23.
25. Huang Q, Yu GP, McCormick SA, Mo J, Datta B, Mahimkar M, Lazarus P, Schaffer AA, Desper R, Schantz SP (2002) Genetic differences detected bycomparative genomic hybridization in head and neck squamous cellcarcinomas from different tumor sites: construction of oncogenetic treesfor tumor progression. Genes Chromosomes Cancer 34 (2) : 224-233.
26. Kaminagakura E, Villa LL, Andreoli MA, Sobrinho JS, Vartanian JG, SoaresFA, Nishimoto IN, Rocha R, Kowalski LP (2011) High-risk humanpapillomavirus in oral squamous cell carcinoma of young patients. Int JCancer 130: 1726-1732.
27. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ (1998) Both Rb/p16INK4a inactivation and telomerase activity arerequired to immortalize human epithelial cells. Nature 396 (6706) : 84-88.
28. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Humanpapillomavirus types in head and neck squamous cell carcinomasworldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 (2) :467-475.
29. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators ofresponse to therapy and survival in oropharyngeal cancer. J Clin Oncol26 (19) : 3128-3137.
30. Lassen P, Eriksen JG, Krogdahl A, Therkildsen MH, Ulhoi BP, Overgaard M, Specht L, Andersen E, Johansen J, Andersen LJ, Grau C, Overgaard J (2011) The influence of HPV-associated p16-expression on acceleratedfractionated radiotherapy in head and neck cancer: evaluation of therandomised DAHANCA 6&7 trial. Radiother Oncol 100 (1) : 49-55.
31. Licitra L, Bernier J, Grandi C, Locati L, Merlano M, Gatta G, Lefebvre JL (2003) Cancer of the larynx. Crit Rev Oncol Hematol 47 (1) : 65-80.
32. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM (2001) Humanpapillomavirus positive squamous cell carcinoma of the oropharynx: aradiosensitive subgroup of head and neck carcinoma. Cancer 92 (4) :805-813.
33. Marklund L, Nñsman A, Ramqvist T, Dalianis T, Munck-Wikland E, Hammarstedt L (2012) Prevalence of human papillomavirus and survivalin oropharyngeal cancer other than tonsil or base of tongue cancer. CancerMed 1 (1) : 82-88.
34. Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated headand neck cancer: a virus-related cancer epidemic. Lancet Oncol 11 (8) :781-789.
35. McDougall JK (1994) Immortalization and transformation of human cells byhuman papillomavirus. Curr Top Microbiol Immunol 186: 101-119.
36. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989) The E6 and E7genes of the human papillomavirus type 16 together are necessary andsufficient for transformation of primary human keratinocytes. J Virol63 (10) : 4417-4421.
37. Negri G, Bellisano G, Zannoni GF, Rivasi F, Kasal A, Vittadello F, AntoniazziS, Faa G, Ambu R, Egarter-Vigl E (2008) P16 ink4a and HPV L1immunohistochemistry is helpful for estimating the behavior oflow-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 32 (11) :1715-1720.
38. Schlecht NF, Brandwein-Gensler M, Nuovo GJ, Li M, Dunne A, Kawachi N, Smith RV, Burk RD, Prystowsky MB (2011) A comparison of clinicallyutilized human papillomavirus detection methods in head and neckcancer. Mod Pathol 24 (10) : 1295-1305.
39. Sethi S, li-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, Quint W, AlbashitiB, Ibrahim M, Kato I (2011) Characteristics and survival of head and neckcancer by HPV status: a cancer registry-based study. Int J Cancer 131:1179-1186.
40. Shah JP, Lydiatt W (1995) Treatment of cancer of the head and neck. CACancer J Clin 45 (6) : 352-368.
41. Shah JP, Patel KJ (2003) Head and Neck Surgery and Oncology. 3rd edn MosbyLtd.
42. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, O'Sullivan B, Waldron J, Cummings B, Kim J, Ringash J, Dawson LA, Gullane P, Siu L, Gillison M, Liu FF (2009) Comparative prognostic value of HPV16 E6mRNA compared with in situ hybridization for human oropharyngealsquamous carcinoma. J Clin Oncol 27 (36) : 6213-6221.
43. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: theimpact of eliminating socioeconomic and racial disparities on prematurecancer deaths. CA Cancer J Clin 61 (4) : 212-236.
44. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH (2007) A novelalgorithm for reliable detection of human papillomavirus in paraffinembedded head and neck cancer specimen. Int J Cancer 121 (11) :2465-2472.
45. Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, Perez CA (2001) Delayed regional metastases, distant metastases, andsecond primary malignancies in squamous cell carcinomas of the larynxand hypopharynx. Laryngoscope 111 (6) : 1079-1087.
46. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, RamosAH, Stojanov P, Carter SL, Voet D, Cortes ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR (2011) The mutational landscape of head and neck squamous cellcarcinoma. Science 333 (6046) : 1157-1160.
47. Sturgis EM, Cinciripini PM (2007) Trends in head and neck cancer incidencein relation to smoking prevalence an emerging epidemic of humanpapillomavirus-associated cancers Cancer 110 (7) : 1429-1435.
48. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE (2008) Chemoselection as a strategy for organ preservation inadvanced oropharynx cancer: response and survival positively associatedwith HPV16 copy number. J Clin Oncol 26 (19) : 3138-3146.